| Bioactivity | Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM)[1]. |
| Invitro | Tagraxofusp (0-1367 pM; 72 h) inhibits pDCs viability, as well as pDC-induced proliferation of MM cells.Tagraxofusp (0-136.7 pM; 2-3 weeks) inhibits osteoclast formation and bone resorption, as well as stabilizes osteoblast formation[1].Tagraxofusp (0-13.67 nM; 48 h) targets tumor-initiating stem-like cells in MM[1]. Cell Viability Assay[1] Cell Line: |
| In Vivo | Tagraxofusp (12-50 μg/kg; i.v.; 5 times per week for 3 weeks) blocks pDC-induced tumor growth and prolongs SCID-hu mice survival in subcutaneous INA-6 MM xenograft model[1].Tagraxofusp (16 μg/kg; i.v.; 5 times per week for 1 weeks) enhances the anti-MM activity of 2.5 mg/kg Pomalidomide in CB-17 mice of subcutaneous MM xenograft model[1]. Animal Model: |
| Name | Tagraxofusp |
| CAS | 2055491-00-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ray A, et al. A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells. Leukemia. 2017 Dec;31(12):2652-2660. |